Clinical Trials

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT06690840 2026-01-05

AZALEA

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

13 enrolled

Breast Neoplasms

NCT04759248 2025-09-09

ATREZZO

55 enrolled

Breast Neoplasms, Neoplasms

NCT03414658 2025-07-02

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

100 enrolled 15 charts

Breast Neoplasms

NCT06533722 2025-06-10

Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

10 enrolled

HER2-negative Metastatic Breast Cancer

NCT03242616 2025-04-17

PemVin vs Vin in Previously Treated Metastatic Breast Cancer

17 enrolled

Breast Neoplasms

NCT04296162 2025-04-17

ORCHID

178 enrolled

Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

Phase 2 Not yet recruiting

HER2-negative Breast Cancer

NCT06653972 2024-10-23

EASOVCWDITHABC

Her2-negative Metastatic Breast Cancer

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT06176534 2024-08-20

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

240 enrolled

Advanced Breast Cancer

NCT03887130 2024-04-30

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

152 enrolled 14 charts

Breast Neoplasms

NCT02954055 2024-02-26

METEORA-II

140 enrolled 11 charts

Phase 2 Not yet recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT06229067 2024-01-29

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

182 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Phase 2 Withdrawn

Breast Neoplasms

NCT02585388 2023-09-06

CHEOPS

120 enrolled

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

123 enrolled

Breast Cancer Metastatic

NCT04304352 2023-06-28

VEX

162 enrolled

Advanced Breast Cancer

NCT00431704 2023-03-24

VinCaT

39 enrolled

Breast Neoplasms

NCT05747326 2023-02-28

Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer

Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT05603013 2022-11-02

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

45 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04848454 2022-10-18

Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

HER2-negative Breast Cancer

NCT04605575 2022-04-26

Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer

208 enrolled

Breast Diseases, Breast Neoplasms

NCT02607215 2022-04-20

Platinum Rechallenge in Patients With Platinum-sensitive mTNBC

84 enrolled

Breast Neoplasms

NCT03254654 2022-04-20

Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

66 enrolled

Advanced Triple-Negative Breast Cancer

NCT04745975 2022-04-20

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT04903652 2022-04-07

Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer

NCT04389073 2022-02-25

Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine

138 enrolled

Breast Neoplasms

NCT04963595 2021-07-15

Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

100 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT04922008 2021-06-10

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

356 enrolled

Breast Neoplasms

NCT01835236 2021-03-30

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

208 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT04681911 2020-12-23

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

71 enrolled

Breast Neoplasms

NCT00006682 2020-08-14

Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

Breast Neoplasms

NCT02362958 2020-07-15

A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

159 enrolled

HER2 Positive Breast Cancer

NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Hormone Receptor Positive Advanced Breast Cancer

NCT04302441 2020-03-10

A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy

550 enrolled

Breast Neoplasms

NCT02628613 2019-11-01

Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations

91 enrolled

Breast Neoplasms

NCT04143906 2019-10-30

Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer

200 enrolled

Breast Neoplasms

NCT03997539 2019-06-25

A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

256 enrolled

Breast Neoplasms

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

40 enrolled

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

184 enrolled

Triple Negative Breast Neoplasms

NCT00130507 2019-02-26

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

14 enrolled

Breast Neoplasms

NCT01185509 2019-01-23

Trastuzumab and Vinorelbine in Advanced Breast Cancer

31 enrolled 11 charts

Breast Neoplasms

NCT00148681 2019-01-15

Preoperative Herceptin and Navelbine for Breast Cancer

49 enrolled